Sorrento Therapeutics (LTS:0L85) Short Percentage of Float


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0L85 vs IMUX, OCUP, KZR: Short Percentage of Float Comparison

For the Biotechnology subindustry, Sorrento Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Short Percentage of Float falls into.


LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price